SYRE

Business Context and Reporting Period

Spyre Therapeutics, Inc. (SYRE) is a clinical-stage biotechnology company focused on developing next-generation therapeutics for inflammatory bowel disease (IBD) and rheumatoid arthritis (RA). The company operates under a single segment and reported for the fiscal year ended December 31, 2024. Following a strategic pivot in 2023 via the acquisition of Pre-Merger Spyre assets, the company's pipeline now centers on extended half-life antibody candidates (SPY001, SPY002, SPY003) and their combinations. The company is headquartered in Waltham, MA, and trades on the Nasdaq Global Select Market.

Key Financial Metrics

Note: The company has no debt obligations listed in the balance sheet liabilities. Liquidity is supported by significant cash reserves and recent equity financings.

Material Changes vs. Prior Period

• Revenue Decline: Revenue dropped to zero in 2024 from $0.9 million in 2023. The 2023 revenue was derived from the legacy Immedica agreement for pegzilarginase, which was terminated in July 2023 following the sale of global rights.
• Net Loss Improvement: Net loss decreased by approximately $130.8 million (39%) year-over-year. This improvement was primarily driven by the absence of a one-time $130.2 million expense for acquired in-process research and development (IPR&D) and an $83.5 million non-cash loss on the change in fair value of a forward contract liability, both incurred in 2023.
• R&D Expense Increase: R&D expenses increased by $73.3 million (82%) to $162.8 million. This increase reflects accelerated development of the new IBD pipeline, including a $43.4 million rise in manufacturing costs and a $34.0 million increase in nonclinical and clinical development costs.
• Capital Raising: The company raised significant capital in 2024, including a $215.9 million underwritten public offering in November and a $168.9 million private placement of Series B Preferred Stock in March, bolstering its cash position.

Guidance, Outlook, and Risks

Outlook and Milestones

• SPY001 (anti-α4β7): Phase 1 trial in healthy volunteers is complete with interim data showing a favorable safety profile and a half-life estimated at >90 days. The company plans to advance to a Phase 2 trial in Ulcerative Colitis (UC) patients in mid-2025.
• SPY002 (anti-TL1A): Two Phase 1 trials in healthy volunteers were initiated in Q4 2024. Interim data is expected in Q2 2025. Phase 2 trials in UC and Rheumatoid Arthritis (RA) are planned for mid-2025.
• SPY003 (anti-IL-23): A Phase 1 trial in healthy volunteers is expected to initiate in Q1 2025.
• Combinations: The company intends to initiate clinical trials for combination therapies (SPY120, SPY130, SPY230) in 2025, subject to regulatory feedback.

Risks and Contingencies

• Material Weakness in Internal Controls: The company identified a material weakness in internal control over financial reporting related to the accounting treatment of preferred stock for earnings per share calculations. This resulted in the restatement of financial statements for 2023 and interim 2024 periods. Remediation is underway but requires validation over a sustained period.
• Liquidity and Capital Needs: While the company has $603.1 million in cash and marketable securities (sufficient for at least one year of operations), it anticipates continued significant losses and will require additional capital to fund future clinical trials and commercialization efforts.
• Third-Party Reliance: The company relies on third-party manufacturers (including WuXi Biologics) for drug supply. Geopolitical tensions and potential legislation (e.g., BIOSECURE Act) pose risks to the supply chain.
• Development Risks: As a clinical-stage company with no approved products, success depends on the safety and efficacy of its candidates, which may fail or be delayed.

Investor Verification Checklist

• Restatement Impact: Verify the specific impact of the financial restatement on historical EPS and the status of the remediation plan for the material weakness in internal controls.
• Cash Burn Rate: Monitor the rate of cash consumption against the $603.1 million balance to assess the runway for operations without further dilution.
• SPY001 Phase 2 Timing: Confirm the initiation date of the Phase 2 UC trial in mid-2025 and the design of the study.
• Paragon Agreement Milestones: Track the achievement of development milestones under the Paragon License Agreements, which trigger payments totaling up to $22.0 million per program.
• Supply Chain Mitigation: Review updates on supply chain diversification strategies to mitigate risks associated with reliance on Chinese manufacturers (WuXi Biologics).